FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Related Topics >> Provenge | Medicare | Dendreon

Medicare panel backs Provenge

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!


A Medicare advisory committee backed Dendreon's prostate cancer vaccine Provenge yesterday, thus increasing the chances federal insurance program will pay for the drug. The treatment costs $93,000 a patient and extends patients' lives by about four months.

The panel's average confidence score (on a scale of 1 to 5) was 3.6 for evidence of an overall survival benefit, according to the Wall Street Journal. The committee also voted that there was inadequate evidence Provenge would help other kinds of patients, such as those who were either sicker than those studied to get Provenge approved or those who were not as sick, the Washington Post notes.

As with FDA advisory panels, the committee's backing isn't binding on the agency. The coverage decision will include a one-month public-comment period and a proposed decision by the end of March, then a final decision by the end of June.

In the first three months following the FDA's approval of Provenge, Dendreon was able to gin a mere $2.8 million in sales as it began to ramp up production. But sales are rising at a fast pace and July saw more than $5 million in new Provenge revenue as the Seattle-based company picks up the pace as it heads towards its blockbuster goal of $1 billion a year.

- get more from HealthDay
read the WSJ Health Blog's coverage
- check out the Washington Post story

ALSO: An experimental drug is showing what some experts say is intriguing effectiveness in treating a major cause of death and disability for men with prostate cancer--tumors that have spread to the bone. The experimental drug, XL184, is the lead drug candidate of Exelixis, a biotechnology company in South San Francisco, CA. Report

Related Articles:
CMS: Data shows moderate support for Provenge use
Medicare's Provenge review comes into clearer focus
Dendreon: Provenge on course to hit blockbuster goal

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Comments (1) | Post a comment
More stories about Provenge   Medicare   Dendreon  


Why did Varun Nanda just quit Dendreon. Why is the man who turned Avastin into a success and then got hired with much fanfare at Dendreon now quitting after only 7 months, before Provenge global operations are even started?

The same thing happened with Ian Clark just 2 months ago.
This is very bad news for Dendreon.

Dendreon = new Sequenom.

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

This question is for testing whether you are a human visitor and to prevent automated spam submissions.